Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad26.ZIKV.001 in healthy adults
NCT03356561Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Sep 2019
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Ad26.ZIKV.001 in Zika virus infection (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Solicited Injection Site (Local) Adverse Events, Number of Participants with Solicited Systemic Adverse Events and 2 more. Started Nov 2017; status: completed.
02
Drugs
Ad26.ZIKV.001
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT03356561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03356561.